Document is current
Any future updates will be listed below
-
Authors
Anastasiou, Panayiotis
Moore, Christopher https://orcid.org/0000-0002-4653-1427
Rana, Sareena
Tomaschko, Mona
Pillsbury, Claire E.
de Castro, Andrea
Boumelha, Jesse
Mugarza, Edurne
de Carné Trécesson, Sophie https://orcid.org/0000-0002-9341-2586
Mikolajczak, Ania
Blaj, Cristina
Goldstone, Robert
Smith, Jacqueline A. M.
Quintana, Elsa
Molina-Arcas, Miriam https://orcid.org/0000-0002-8176-8948
Downward, Julian https://orcid.org/0000-0002-2331-4729
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (RASImmune)
EC | Horizon 2020 Framework Programme (RASImmune)
- License Information
-
More Information
Article History
Received: 23 January 2024
Accepted: 3 September 2024
First Online: 25 September 2024
Competing interests
: J.D. has acted as a consultant for AstraZeneca, Jubilant, Theras, Roche and Vividion and has funded research agreements with Bristol Myers Squibb, Revolution Medicines and AstraZeneca. S.C.T. has acted as a consultant for Revolution Medicines. C.B., E.Q. and J.A.M.S. are employees of Revolution Medicines. The other authors declare that they have no competing interests.
